Osteonecrosis of the Jaw Incidence with Bisphosphonates and Denosumab

confidence: high · 1 sources

⚠
Working research — not a recommendation.

This page records what the evidence says a policy does, not what anyone should do about it. It has been synthesized from the cited sources but has not been independently reviewed.

What the evidence says

The only source on this page reports MRONJ (medication-related osteonecrosis of the jaw) incidence in high-dose antiresorptive drug (ARD) use in cancer settings. It gives 6.7% in bisphosphonate users and 10% in denosumab users. It gives up to 15% in patients who received both drug types in sequence. These figures are cited from earlier studies, not measured in the paper itself. They are point estimates with no confidence intervals or sample sizes. The 15% figure is also worded as an upper bound ("can even reach"), so its magnitude is the least certain of the three.

The page has no incidence figure for low-dose use, such as osteoporosis dosing. It also has no figure for people who take no antiresorptive drug. Without that comparison group, the numbers above describe how often MRONJ occurs under each regimen. They do not show how much of it each drug adds.

The source's own retrospective longitudinal cohort looked at lamina dura (LD) thickness, a radiographic marker. LD thickness stayed stable in controls and increased in ARD-treated patients (p < 0.001). Within the ARD group, 30.6% showed no change, 55.4% developed mild thickening, and 13.8% developed marked thickening. So thickening is common but not universal in treated patients.

LD thickening was not directly associated with MRONJ (p = 0.39). The authors note that MRONJ is multifactorial and that tooth extraction may modify this relationship. On this page, the radiographic change does not link ARD use to the jaw outcome. The claims state no causal mechanism for MRONJ itself.

Where the evidence splits

No contradictions in the current sources.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

Findings

High-dose antiresorptive therapy increases MRONJ incidence in oncologic patients, with the highest reported figure after sequential bisphosphonate and denosumab treatment

confidence — direction: highconfidence — magnitude: medium for 6.7% and 10%; low for the 15% upper boundconsensus: thin. One source reports all three figures, and it cites earlier work.
mechanism
not established in the claims
effect
increases MRONJ incidence to 6.7% with high-dose bisphosphonates, to 10% with high-dose denosumab, and up to 15% with sequential treatment with both. No comparison-group baseline is given.
conditions / moderators
oncologic settings with high-dose use only. The figures are cited from prior studies (references 12-14), not original findings. They are point estimates without confidence intervals. The 15% figure is an upper-bound range.

Antiresorptive therapy increases lamina dura thickness over time

confidence — direction: highconfidence — magnitude: highconsensus: thin. One cohort reports it.
mechanism
not established in the claims
effect
LD thickness remained stable in controls and increased in ARD-treated patients (p < 0.001). Within the ARD group, 30.6% showed no change, 55.4% developed mild thickening, and 13.8% developed marked thickening.
conditions / moderators
retrospective longitudinal cohort. Three blinded radiologists scored the images, with consensus scoring. Individual response varies.

Lamina dura thickening shows no measured association with MRONJ

confidence — direction: highconfidence — magnitude: mediumconsensus: thin. One cohort reports it, using two independent tests (Chi-square and Kaplan-Meier).
mechanism
not established. The authors describe MRONJ as multifactorial.
effect
no measured effect (p = 0.39 for a direct association)
conditions / moderators
the authors note that tooth extraction may modify this relationship. The claims do not quantify that modification.